Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;358(9):e70088.
doi: 10.1002/ardp.70088.

Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention

K Sruthi  1 , S L Manju  1
Affiliations

Development of 1,2,3-Triazoles as Dual Enzyme Inhibitors Targeting α-Amylase and α-Glucosidase for Type 2 Diabetes Intervention

K Sruthi et al. Arch Pharm (Weinheim). 2025 Sep.

Abstract

A series of fifteen 1,2,3-triazole derivatives 6(a-o) were developed and evaluated for their inhibitory effects on carbohydrate-hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α-amylase, α-glucosidase, and antioxidant activities. Notably, the compounds 6a, 6d, 6g, 6h, 6k, 6l, and 6n exhibited dual inhibition against both enzymes. Among them, compound 6a exhibited the most potent α-glucosidase inhibition (IC50 = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC50 = 21.07 ± 0.05 µM). Meanwhile, compound 6h demonstrated strong α-amylase inhibition (IC50 = 84.46 ± 1.14 µM) compared with standard acarbose (IC50 = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds 6a and 6h indicated moderate cytotoxicity, with IC50 values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds 6(a-o), with IC50 values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.

Keywords: 1,2,3‐triazole; ADME; MTT assay; antioxidant; molecular docking; α‐glucosidase and α‐amylase inhibition.

PubMed Disclaimer

References

    1. S. Katiyar, S. Ahmad, A. Kumar, et al., “Design, Synthesis, and Biological Evaluation of 1,4‐Dihydropyridine‐Indole as a Potential Antidiabetic Agent via GLUT4 Translocation Stimulation,” Journal of Medicinal Chemistry 67 (2024): 11957–11974.
    1. L. M. Aroua, H. R. Almuhaylan, F. M. Alminderej, et al., “A Facile Approach Synthesis of Benzoylaryl Benzimidazole as Potential α‐Amylase and α‐Glucosidase Inhibitor With Antioxidant Activity,” Bioorganic Chemistry 114 (2021): 105073, https://doi.org/10.1016/j.bioorg.2021.105073.
    1. A. Hajlaoui, A. Assel, H. Lazrag, et al., “Design, Synthesis and Biological Evaluation of Novel Benzopyran Derivatives as Potential α‐Amylase Inhibitors: An Investigation by Experimental and Computational Studies,” Journal of Molecular Structure 1273 (2023): 134227, https://doi.org/10.1016/j.molstruc.2022.134227.
    1. M. Kazempour‐Dizaji, S. Mojtabavi, A. Sadri, A. Ghanbarpour, M. A. Faramarzi, and L. Navidpour, “Arylureidoaurones: Synthesis, In Vitro α‐Glucosidase, and α‐Amylase Inhibition Activity,” Bioorganic Chemistry 139 (2023): 106709, https://doi.org/10.1016/j.bioorg.2023.106709.
    1. P. Ritu, P. Sharma, G. D. Gupta, and V. Asati, “Design, Synthesis and Antidiabetic Study of Triazole Clubbed Indole Derivatives as α‐Glucosidase Inhibitors,” Bioorganic Chemistry 139 (2023): 106750, https://doi.org/10.1016/j.bioorg.2023.106750.

MeSH terms

LinkOut - more resources